GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Cann Regulatory News (OCTP)

Share Price Information for Oxford Cann (OCTP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.115
Bid: 0.10
Ask: 0.13
Change: -0.005 (-4.17%)
Spread: 0.03 (30.00%)
Open: 0.12
High: 0.18
Low: 0.115
Prev. Close: 0.115
OCTP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Presentation Webinar to Retail Investors

4 Jun 2021 07:00

RNS Number : 7967A
Oxford Cannabinoid Tech.Holdings
04 June 2021
 

RNS Reach

 

4 June 2021

 

 

Oxford Cannabinoid Technologies Holdings plc

 

 

Company presentation webinar to retail investors

 

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), a UK based pharmaceutical company focussed on developing cannabinoid-based prescription medicines approved by regulatory agencies, is pleased to announce that its CEO, Dr. John Lucas, and Executive Chairman, Neil Mahapatra, will conduct two live presentations to retail investors following its recent admission to trading on the Main Market of the London Stock Exchange.

 

The presentations will provide an opportunity for potential investors to learn about the Company and its outlook for the year ahead.

 

The live webinars, hosted by AJ Bell/Shares and Yellowstone Advisers, will take place on Tuesday 8th June 2021 at 19.45 and Thursday 10 June 2021 at 13.00, respectively.

 

The online presentations are open to all existing and potential investors and registration is free. Questions can be submitted during the presentation and will be addressed at the end.  

 

To register, please go to:

 

- AJ Bell/Shares - https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-080621 

- Yellowstone - https://www.yellowstoneadvisory.com/event-details/oxford-cannabinoid-technologies-plc-webinar 

 

 

For more information please contact:

 

Oxford Cannabinoid Technologies Holdings plc - Dr John Lucas (CEO)

079 5687 3125 / john@oxcantech.com 

 

PR Advisers: Acuitas Communications - James Gittings/Simon Nayyar

020 3848 2810 / james.gittings@acuitascomms.com 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADZGGVVFDGMZM
Date   Source Headline
6th Jun 20247:00 amRNSCancellation of Listing
31st May 20247:00 amRNSUpdated Shareholder Engagement
17th May 20244:30 pmRNSUpdated Shareholder Information
8th May 20247:00 amRNSIntended Cancellation of Listing
11th Apr 202411:26 amRNSAppointment of Phase I Clinical Trial CRO
3rd Apr 20248:00 amRNSOCT Company Update with Doceo
26th Mar 202410:56 amRNSOxford Cannabinoid Technologies video with Doceo
18th Mar 20247:00 amRNSAppointment of Hybridan as Adviser
29th Feb 20247:02 amRNSDirectorate Appointment
29th Feb 20247:01 amRNSDirectorate Changes
29th Feb 20247:00 amRNSTotal Voting Rights
28th Feb 20245:35 pmRNSTR-1: NOTIFICATION OF MAJOR HOLDINGS
28th Feb 20245:34 pmRNSTR-1: NOTIFICATION OF MAJOR HOLDINGS
28th Feb 20245:34 pmRNSTR-1: NOTIFICATION OF MAJOR HOLDINGS
26th Feb 20241:07 pmRNSDirectors’ Dealings
19th Feb 20241:52 pmRNSResult of General Meeting
16th Feb 20247:00 amRNSCompletion of Capital Reorganisation
15th Feb 20247:00 amRNSSubscription
14th Feb 202412:53 pmRNSCapital Reorganisation
9th Feb 20247:00 amRNSEdison issues update on OCTP
2nd Feb 20243:17 pmRNSNotice of General Meeting & Posting of Circular
2nd Feb 20243:13 pmRNSConvertible Loan Note Agreements
30th Jan 20247:04 amRNSFundraising and Proposed Capital Reorganisation
30th Jan 20247:02 amRNSR&D Tax Credit
30th Jan 20247:00 amRNSHalf-year Report
23rd Jan 20247:00 amRNSNotice of Results
10th Jan 20247:00 amRNSPatent Applications
14th Nov 20237:00 amRNSDirectorate Appointment
24th Oct 20237:00 amRNSTR-1: Notification of major holdings
20th Oct 20237:01 amRNSTR-1: Notification of major holdings
20th Oct 20237:00 amRNSDirector Dealing
10th Oct 20237:00 amRNSPhase I Clinical Trial Results
29th Sep 20237:00 amRNSResult of AGM
25th Sep 20237:00 amRNSFinal Dose Administered
5th Sep 20234:18 pmRNSNotice of AGM
31st Aug 20237:00 amRNS2023 Final Results
22nd Aug 20237:00 amRNSNotice of Results
27th Jul 20237:00 amRNSFirst Dose Administered & Pain Specialist Adviser
17th Jul 20231:16 pmRNSDirector/PDMR Share Purchases
17th Jul 20237:00 amRNSExpansion into oncology
12th Jul 20237:00 amRNSInvestor Presentation and Q&A – Programmes update
15th Jun 20239:50 amRNSOCTP update from Doceo
8th Jun 20237:00 amRNSAppointment of Chief Medical Officer
17th May 20237:00 amRNSMHRA & REC 2 Approval for Phase 1 Clinical Trial
12th Apr 20237:00 amRNSDirectorate Change, Renewal of Licence & Update
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
13th Mar 20234:35 pmRNSPrice Monitoring Extension
7th Mar 202311:05 amRNSSecond Price Monitoring Extn
7th Mar 202311:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.